These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Effect of immune processes on the growth and regression of malignant tumors]. Russo V; Russo L Vopr Onkol; 1974; 20(6):68-75. PubMed ID: 4603500 [No Abstract] [Full Text] [Related]
7. Immunology and the surgeon. Kettlewell M; Steer H; Gill PG; Morris PJ Surg Annu; 1979; 11():1-23. PubMed ID: 116377 [No Abstract] [Full Text] [Related]
8. Malignancy as a complication of immunosuppressive therapy. Leibowitz S; Schwartz RS Adv Intern Med; 1971; 17():95-123. PubMed ID: 4145004 [No Abstract] [Full Text] [Related]
10. Mechanisms of tumor-induced immunological deficiencies and their possible significance in relation to the use of immunopotentiators in tumor-bearing hosts. Kerbel RS Biomedicine; 1974 Jul; 21(7):253-61. PubMed ID: 4547979 [No Abstract] [Full Text] [Related]
11. Transfer factor in cellular immunity. Lawrence HS Harvey Lect; 1974; 68():239-350. PubMed ID: 4616018 [No Abstract] [Full Text] [Related]
12. Tumor immunology. McKhann CF; Yarlott MA CA Cancer J Clin; 1975; 25(4):187-97. PubMed ID: 805638 [No Abstract] [Full Text] [Related]
18. Neuraminidase induced immunospecific destruction of transplantable experimental tumors. Sethi KK; Teschner M Postepy Hig Med Dosw; 1974; 28(1):103-20. PubMed ID: 4816378 [No Abstract] [Full Text] [Related]
19. Tumor immunology. Klein G Transplant Proc; 1973 Mar; 5(1):31-41. PubMed ID: 4348706 [No Abstract] [Full Text] [Related]
20. Prospects for tumor immunotherapy in man, with emphasis on its use as an adjunct to surgery for primary operable cancer. Southam CM J Med Liban; 1975; 28(1):43-66. PubMed ID: 1107552 [No Abstract] [Full Text] [Related] [Next] [New Search]